Health Trials

About this trial

This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.

Eligibility criteria

Qualifiers

heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;

age 18 to 80 years.

Disqualifiers

co-occurrence of other neurological disorders;

implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);

severe claustrophobia;

intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);

Trial design

Treatments tested in this trial

  • PET scan
  • neuroQWERTY

Treatment groups

25 Participants
are divided into 2 treatment groups

Locations

3
Canada
Pacific Parkinson's Research Centre | University of British Columbia VancouverBritish Columbia, Canada
United States
Oregon Health & Science University97239, PortlandOregon, United States
University of Washington98108-1595, SeattleWashington, United States

Sponsors and collaborators

Pacific Parkinson's Research Centre

Lead sponsor

University of British Columbia

Collaborator

University of Washington

Collaborator

Oregon Health and Science University

Collaborator

Simon Fraser University

Collaborator

Michael J. Fox Foundation for Parkinson's Research

Collaborator

Silverstein Foundation

Collaborator

Weston Brain Institute

Collaborator

Source ClinicalTrials.gov